Bookmark
Forward
QuickView for Chlorthalidone (compound)
PubChem
| Name: | Chlorthalidone |
|---|---|
| PubChem Compound ID: | 2732 |
| Description: | A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic. |
| Molecular formula: | C14H11ClN2O4S |
| Molecular weight: | 338.767 g/mol |
| Synonyms: |
Hygroton; Natriuran; Thalitone; (+-)-Chlorthalidone; 1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline; Chlortalidonum [INN-Latin]; Isoren; D00272; 5-22-07-00602 (Beilstein Handbook Reference); G-33182.
show more » |
DrugBank
Identification
| Name: | Chlorthalidone |
|---|---|
| Name (isomeric): | DB00310 |
| Drug Type: | small molecule |
| Description: | A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic. |
| Synonyms: |
Clodronic Acid; Chlorphthalidone; Chlorphthalidolone; Chlorothalidone; Chlorthalidon; Chlortalidone
|
| Brand: | Isoren, Zambesil, Igroton, Higroton, Natriuran, Hydro-Long, Oradil, Renon, Tenoretic, Hygroton, Thalitone, Phthalamudine, Phthalamodine, Saluretin |
| Brand name mixture: | Tenoretic(chlorthalidone + atenolol) |
| Category: | Sodium Chloride Symporter Inhibitors, Diuretics, Antihypertensive Agents |
| CAS number: | 77-36-1 |
Pharmacology
| Indication: | For management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. |
|---|---|
| Pharmacology: | Chlorthalidone, a monosulfonamyl diuretic, differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Chlorthalidone is used alone or with atenolol in the management of hypertension and edema. |
| Mechanism of Action: | Chlorthalidone inhibits sodium ion transport across the renal tubular epithelium in the cortical diluting segment of the ascending limb of the loop of Henle. By increasing the delivery of sodium to the distal renal tubule, Chlorthalidone indirectly increases potassium excretion via the sodium-potassium exchange mechanism. |
| Absorption: | Absorbed relatively rapidly after oral administration. |
| Protein binding: | High (75% [58% to albumin]) |
| Biotransformation: | Liver |
| Route of elimination: | The major portion of the drug is excreted unchanged by the kidneys. |
| Half Life: | 40 hours |
| Toxicity: | Symptoms of overdose include nausea, weakness, dizziness and disturbances of electrolyte balance. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
